- Joined
- May 17, 2010
- Messages
- 3,431
- Reaction score
- 145
- Points
- 5,266
- Attending Physician
Advertisement - Members don't see this ad
Hey guys...I don't really come around the pharmacy forums much, but I saw this and was wondering what you all think.
"Chapman University and Keck Graduate Institute (KGI) will be partnering to establish a joint School of BioPharmacy, initially launching at the KGI campus in Claremont, California. The school will focus on preparing graduate pharmacists for professions in biotechnology and the pharmaceutical industry as well as for modern pharmacy practice. This new school will open in fall 2014, pending national accreditation.
The new Chapman-KGI School of BioPharmacy will reorient the doctor of pharmacy degree toward crucial developments in pharmacogenomics. The program will reflect rapidly developing changes in the field, including the growth of personalized medicine, the delivery of biomolecules, changes in drug and device development, and progress in clinical trials and team-based operating environments. The curriculum is planned to equip graduates to become licensed pharmacists with sophisticated knowledge of the applied life sciences for modern health care practice, and experience with therapeutics, therapy management, and regulatory affairs to shape discovery in biotechnology and pharmaceutical companies.
Chapman-KGI School of BioPharmacy is expected to grow to a full enrollment of 320 students in the four-year PharmD program."
"Chapman University and Keck Graduate Institute (KGI) will be partnering to establish a joint School of BioPharmacy, initially launching at the KGI campus in Claremont, California. The school will focus on preparing graduate pharmacists for professions in biotechnology and the pharmaceutical industry as well as for modern pharmacy practice. This new school will open in fall 2014, pending national accreditation.
The new Chapman-KGI School of BioPharmacy will reorient the doctor of pharmacy degree toward crucial developments in pharmacogenomics. The program will reflect rapidly developing changes in the field, including the growth of personalized medicine, the delivery of biomolecules, changes in drug and device development, and progress in clinical trials and team-based operating environments. The curriculum is planned to equip graduates to become licensed pharmacists with sophisticated knowledge of the applied life sciences for modern health care practice, and experience with therapeutics, therapy management, and regulatory affairs to shape discovery in biotechnology and pharmaceutical companies.
Chapman-KGI School of BioPharmacy is expected to grow to a full enrollment of 320 students in the four-year PharmD program."
